{"corpus_id":43873758,"paper_sha":"a57eea4bfb4fad51a82168c63a555a1c5c572e51","doi":"10.3748/wjg.v21.i17.5287","arxiv_id":null,"pmid":25954102,"pmcid":"PMC4419069","mag_id":1031831829,"dblp_id":null,"acl_id":null,"title":"Radiofrequency ablation for single hepatocellular carcinoma 3 cm or less as first-line treatment.","year":2015,"publication_date":"2015-05-07","venue":"World Journal of Gastroenterology","journal":{"name":"World journal of gastroenterology","pages":"\n          5287-94\n        ","volume":"21 17"},"journal_issn":null,"journal_title":null,"publication_types":["Study","JournalArticle"],"pubmed_pub_types":["Evaluation Study","Journal Article","Multicenter Study","Research Support, Non-U.S. Gov't"],"s2_fields_of_study":["Medicine"],"reference_count":26,"citation_count":29,"influential_citation_count":2,"is_open_access":false,"arxiv_categories":null,"arxiv_license":null,"arxiv_journal_ref":null,"mesh_headings":[{"d":"Adult","mj":false,"ui":"D000328"},{"d":"Aged","mj":false,"ui":"D000368"},{"d":"Aged, 80 and over","mj":false,"ui":"D000369"},{"d":"Carcinoma, Hepatocellular","mj":false,"qs":[{"q":"mortality","mj":false,"ui":"Q000401"},{"q":"secondary","mj":false,"ui":"Q000556"},{"q":"surgery","mj":true,"ui":"Q000601"}],"ui":"D006528"},{"d":"Catheter Ablation","mj":true,"qs":[{"q":"adverse effects","mj":false,"ui":"Q000009"},{"q":"mortality","mj":false,"ui":"Q000401"}],"ui":"D017115"},{"d":"Chi-Square Distribution","mj":false,"ui":"D016009"},{"d":"China","mj":false,"ui":"D002681"},{"d":"Disease Progression","mj":false,"ui":"D018450"},{"d":"Female","mj":false,"ui":"D005260"},{"d":"Humans","mj":false,"ui":"D006801"},{"d":"Kaplan-Meier Estimate","mj":false,"ui":"D053208"},{"d":"Liver Neoplasms","mj":false,"qs":[{"q":"mortality","mj":false,"ui":"Q000401"},{"q":"pathology","mj":false,"ui":"Q000473"},{"q":"surgery","mj":true,"ui":"Q000601"}],"ui":"D008113"},{"d":"Male","mj":false,"ui":"D008297"},{"d":"Middle Aged","mj":false,"ui":"D008875"},{"d":"Multivariate Analysis","mj":false,"ui":"D015999"},{"d":"Neoplasm Recurrence, Local","mj":false,"ui":"D009364"},{"d":"Odds Ratio","mj":false,"ui":"D016017"},{"d":"Patient Selection","mj":false,"ui":"D018579"},{"d":"Proportional Hazards Models","mj":false,"ui":"D016016"},{"d":"Retrospective Studies","mj":false,"ui":"D012189"},{"d":"Risk Factors","mj":false,"ui":"D012307"},{"d":"Time Factors","mj":false,"ui":"D013997"},{"d":"Treatment Outcome","mj":false,"ui":"D016896"},{"d":"Tumor Burden","mj":false,"ui":"D047368"}],"chemicals":null,"comments_corrections":null,"source_flags":5,"s2_open_access_pdf_url":null,"s2_open_access_landing_url":null,"s2_open_access_license":null,"s2_open_access_status":null,"pmc_open_access_pdf_url":null,"pmc_open_access_landing_url":null,"pmc_open_access_license":null,"pmc_open_access_status":null,"unpaywall_open_access_pdf_url":null,"unpaywall_open_access_landing_url":null,"unpaywall_open_access_license":null,"unpaywall_open_access_status":null,"abstract":"AIM\nTo evaluate long-term outcomes of radiofrequency (RF) ablation as first-line therapy for single hepatocellular carcinoma (HCC) ≤ 3 cm and to determine survival and prognostic factors.\n\n\nMETHODS\nWe included all 184 patients who underwent RF ablation as a first-line treatment for single HCC ≤ 3 cm between April 2005 and December 2013. According to the criteria of Livraghi, the 184 patients were divided into two groups: those suitable for surgical resection (84 cases) and those unsuitable for surgical resection (100 cases). The primary endpoints were the overall survival (OS) rate and safety; the secondary endpoints were primary technique effectiveness and recurrence rate.\n\n\nRESULTS\nThere were 19 (10.3%) cases of ablation related minor complications. The complete tumor ablation rate after one RF session was 97.8% (180/184). The rate of local tumor progression, extrahepatic metastases and intrahepatic distant recurrence were 4.9% (9/184), 9.8% (18/184) and 37.5% (69/184), respectively. In the 184 patients, the 1-, 3-, and 5-year OS rates were 99.5%, 81.0%, and 62.5%, respectively. The 1-, 3-, and 5-year OS rates were 100%, 86.9%, and 71.4%, respectively, in those suitable for surgical resection and 99.0%, 76.0%, and 55.0%, respectively, in those unsuitable for surgical resection (P = 0.021). On univariate and multivariate analyses, poorer OS was associated with Child-Pugh B class and portal hypertension (P < 0.05).\n\n\nCONCLUSION\nRF ablation is a safe and effective treatment for single HCC ≤ 3 cm. The OS rate of patients suitable for surgical resection was similar to those reported in surgical series.","claims":[{"public_id":"cl_43ce555c34c7b85ed8e622e566179e15","status":"active","text":"Child-Pugh B class and portal hypertension were associated with poorer overall survival on univariate and multivariate analyses.","confidence":0.93,"contributors":[{"id":1,"public_id":"12632b8b5f","public_label":"Anonymous (12632b8b5f)","roles":["extraction"],"url":"https://sah.borca.ai/u/12632b8b5f"}],"url":"https://sah.borca.ai/claims/cl_43ce555c34c7b85ed8e622e566179e15"},{"public_id":"cl_6e9eeae52abb4e1b1b720bfc05321041","status":"active","text":"One-, 3-, and 5-year overall survival in the full cohort was 99.5%, 81.0%, and 62.5%, respectively.","confidence":0.97,"contributors":[{"id":1,"public_id":"12632b8b5f","public_label":"Anonymous (12632b8b5f)","roles":["extraction"],"url":"https://sah.borca.ai/u/12632b8b5f"}],"url":"https://sah.borca.ai/claims/cl_6e9eeae52abb4e1b1b720bfc05321041"},{"public_id":"cl_d2399cf69918a1f8f5143e6849c5fe12","status":"active","text":"Overall survival was higher in patients suitable for surgical resection than in those unsuitable for surgical resection, with 1-, 3-, and 5-year survival of 100%, 86.9%, and 71.4% versus 99.0%, 76.0%, and 55.0%.","confidence":0.96,"contributors":[{"id":1,"public_id":"12632b8b5f","public_label":"Anonymous (12632b8b5f)","roles":["extraction"],"url":"https://sah.borca.ai/u/12632b8b5f"}],"url":"https://sah.borca.ai/claims/cl_d2399cf69918a1f8f5143e6849c5fe12"},{"public_id":"cl_15f443b681dc1485ec388214af4021cf","status":"active","text":"Radiofrequency ablation as first-line therapy for single hepatocellular carcinoma 3 cm or less produced a 97.8% complete tumor ablation rate after one session and a 10.3% minor complication rate.","confidence":0.98,"contributors":[{"id":1,"public_id":"12632b8b5f","public_label":"Anonymous (12632b8b5f)","roles":["extraction"],"url":"https://sah.borca.ai/u/12632b8b5f"}],"url":"https://sah.borca.ai/claims/cl_15f443b681dc1485ec388214af4021cf"},{"public_id":"cl_7b98dbf23928acb7b3eadd4ae1ae24f1","status":"active","text":"Radiofrequency ablation is a safe and effective treatment option for single hepatocellular carcinoma 3 cm or less.","confidence":0.95,"contributors":[{"id":1,"public_id":"12632b8b5f","public_label":"Anonymous (12632b8b5f)","roles":["extraction"],"url":"https://sah.borca.ai/u/12632b8b5f"}],"url":"https://sah.borca.ai/claims/cl_7b98dbf23928acb7b3eadd4ae1ae24f1"}],"concepts":[{"public_id":"co_54bca6333bfe041c3ee528b4b59b09fa","status":"active","name":"radiofrequency ablation","description":"A thermal local treatment that destroys tumor tissue using radiofrequency-generated heat.","types":["treatment"],"aliases":["RF ablation","RF"],"contributors":[{"id":1,"public_id":"12632b8b5f","public_label":"Anonymous (12632b8b5f)","roles":["extraction"],"url":"https://sah.borca.ai/u/12632b8b5f"}],"url":"https://sah.borca.ai/concepts/co_54bca6333bfe041c3ee528b4b59b09fa"},{"public_id":"co_70cb0bb66344fc29a58d33eb46498424","status":"active","name":"portal hypertension","description":"Abnormally elevated pressure in the portal venous system.","types":["clinical condition"],"aliases":[],"contributors":[{"id":1,"public_id":"12632b8b5f","public_label":"Anonymous (12632b8b5f)","roles":["extraction"],"url":"https://sah.borca.ai/u/12632b8b5f"}],"url":"https://sah.borca.ai/concepts/co_70cb0bb66344fc29a58d33eb46498424"},{"public_id":"co_9b765d64c773ac2ae488ae1fabd43375","status":"active","name":"first-line treatment","description":"The initial treatment chosen as the primary therapy for a patient.","types":["treatment strategy"],"aliases":[],"contributors":[{"id":1,"public_id":"12632b8b5f","public_label":"Anonymous (12632b8b5f)","roles":["extraction"],"url":"https://sah.borca.ai/u/12632b8b5f"}],"url":"https://sah.borca.ai/concepts/co_9b765d64c773ac2ae488ae1fabd43375"},{"public_id":"co_a051f81cd20703b54b21d2730f5d1388","status":"active","name":"surgical resection suitability","description":"Eligibility for surgical removal of the tumor according to the Livraghi criteria.","types":["patient classification"],"aliases":["suitable for surgical resection","unsuitable for surgical resection"],"contributors":[{"id":1,"public_id":"12632b8b5f","public_label":"Anonymous (12632b8b5f)","roles":["extraction"],"url":"https://sah.borca.ai/u/12632b8b5f"}],"url":"https://sah.borca.ai/concepts/co_a051f81cd20703b54b21d2730f5d1388"},{"public_id":"co_a33dd5bcde18d48dd1f212aaac80eee6","status":"active","name":"complete tumor ablation rate","description":"The proportion of treated tumors fully eradicated after a radiofrequency ablation session.","types":["outcome"],"aliases":["complete ablation rate"],"contributors":[{"id":1,"public_id":"12632b8b5f","public_label":"Anonymous (12632b8b5f)","roles":["extraction"],"url":"https://sah.borca.ai/u/12632b8b5f"}],"url":"https://sah.borca.ai/concepts/co_a33dd5bcde18d48dd1f212aaac80eee6"},{"public_id":"co_a84e5d63ea4f5e3dd904035b31c03781","status":"active","name":"safety","description":"The occurrence of treatment-related adverse events and complications.","types":["outcome"],"aliases":[],"contributors":[{"id":1,"public_id":"12632b8b5f","public_label":"Anonymous (12632b8b5f)","roles":["extraction"],"url":"https://sah.borca.ai/u/12632b8b5f"}],"url":"https://sah.borca.ai/concepts/co_a84e5d63ea4f5e3dd904035b31c03781"},{"public_id":"co_ada506b95b89b85bd9c31287e15f3d4a","status":"active","name":"minor complications","description":"Non-major adverse events related to ablation treatment.","types":["adverse event"],"aliases":[],"contributors":[{"id":1,"public_id":"12632b8b5f","public_label":"Anonymous (12632b8b5f)","roles":["extraction"],"url":"https://sah.borca.ai/u/12632b8b5f"}],"url":"https://sah.borca.ai/concepts/co_ada506b95b89b85bd9c31287e15f3d4a"},{"public_id":"co_b888e58894f2456faf4a98a9d801bf5b","status":"active","name":"Child-Pugh B class","description":"A Child-Pugh liver function category indicating moderate hepatic impairment.","types":["clinical score"],"aliases":["Child-Pugh B"],"contributors":[{"id":1,"public_id":"12632b8b5f","public_label":"Anonymous (12632b8b5f)","roles":["extraction"],"url":"https://sah.borca.ai/u/12632b8b5f"}],"url":"https://sah.borca.ai/concepts/co_b888e58894f2456faf4a98a9d801bf5b"},{"public_id":"co_ce63a8a65e705b3aab1acf4d63e630dc","status":"active","name":"overall survival","description":"The proportion of patients alive after a specified follow-up period.","types":["outcome"],"aliases":["OS"],"contributors":[{"id":1,"public_id":"12632b8b5f","public_label":"Anonymous (12632b8b5f)","roles":["extraction"],"url":"https://sah.borca.ai/u/12632b8b5f"}],"url":"https://sah.borca.ai/concepts/co_ce63a8a65e705b3aab1acf4d63e630dc"},{"public_id":"co_f032cd2fa591d0c2e623baf756e435e2","status":"active","name":"single hepatocellular carcinoma 3 cm or less","description":"A solitary hepatocellular carcinoma with a maximum diameter of 3 cm or less.","types":["condition"],"aliases":["single HCC ≤ 3 cm","single HCC 3 cm or less"],"contributors":[{"id":1,"public_id":"12632b8b5f","public_label":"Anonymous (12632b8b5f)","roles":["extraction"],"url":"https://sah.borca.ai/u/12632b8b5f"}],"url":"https://sah.borca.ai/concepts/co_f032cd2fa591d0c2e623baf756e435e2"}],"external_ids":{"DOI":"10.3748/wjg.v21.i17.5287","ArXiv":null,"PubMed":25954102,"PubMedCentral":"PMC4419069","MAG":1031831829,"DBLP":null,"ACL":null},"open_access":{"is_open_access":false,"pdf_url":null,"landing_url":"https://sah.borca.ai/papers/43873758","source":null,"pdf_url_source":null,"license":null,"reason":"pdf_url_not_indexed"},"reference_availability":{"status":"available","references_indexed":true,"full_text_available":false,"full_text_source":null,"count_basis":"semantic_scholar_metadata","extraction_status":"not_applicable","reason":null},"source":{"provider":"episteme2","base_corpus":"semantic_scholar_dump","freshness_mode":"unknown","basis":["semantic_scholar_metadata","postgres_metadata"],"limits":["paper metadata is based on indexed upstream scholarly datasets","claims and concepts are available only for extracted papers","absence of claims or concepts means no extracted graph data is available in this response"],"status":"available","degraded":false,"degraded_reasons":[],"diagnostics":{"status":"available","degraded":false,"degraded_reasons":[],"metadata_status":"available","graph_status":"available","abstract_status":"available"},"source_flags":5},"paper_id":633835,"paper_uid":"3af3ddd8-6abe-481d-a45f-4089a768df54","canonical_identity":{"paper_id":633835,"paper_uid":"3af3ddd8-6abe-481d-a45f-4089a768df54","identity_status":"available","lookup_basis":"semantic_scholar_external_id","compatibility_path":"corpus_id"},"url":"https://sah.borca.ai/papers/43873758"}